Classification tree model analysis of influencing factors for hepatocyte steatosis in patients with chronic hepatitis B
10.3969/j.issn.1001-5256.2016.03.015
- VernacularTitle:慢性乙型肝炎患者肝细胞脂肪变性影响因素的分类树模型分析
- Author:
Peng WANG
1
;
Zhiqiao ZHANG
;
Kaifu KANG
Author Information
1. Department of Infectious Diseases, The First People′s Hospital of Shunde, foshan, Guangdong 528300, China
- Publication Type:Research Article
- Keywords:
hepatitis B, chronic;
fatty liver;
classification tree model;
risk factors
- From:
Journal of Clinical Hepatology
2016;32(3):476-479
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the influencing factors for hepatocyte steatosis in patients with chronic hepatitis B (CHB) and the high-risk population by classification tree model analysis, and to establish a simple method to assess the risk of hepatocyte steatosis in CHB patients. MethodsThe clinical data and pathological results of the CHB patients who underwent liver biopsy in Department of Infectious Diseases, The First People's Hospital of Shunde, from January 2006 and December 2014 were collected. The classification tree model was applied to analyze the influencing factors for hepatocyte steatosis, and index value curve, misclassification matrix, and error of estimation were applied for overall evaluation of classification results of the classification tree model. ResultsThe influencing factors for hepatocyte steatosis in CHB patients were body mass index (BMI), total cholesterol, and low-density lipoprotein, and the most important factor was BMI. This classification tree model had a sensitivity of 84.3%, a specificity of 81.5%, an accuracy of 82.9%, and an error of estimation of 0.171, suggesting that this model was well fitted. ConclusionClassification tree model analysis shows that the pathogenesis of hepatocyte steatosis in CHB patients is closely related to the influencing factors BMI, total cholesterol, and low-density lipoprotein. A simple classification method is established based on these factors to evaluate the risk of hepatocyte steatosis in CHB patients. It is necessary to conduct further clinical studies to investigate the clinical value of this method.
